Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin aspart - Novo Nordisk

Drug Profile

Insulin aspart - Novo Nordisk

Alternative Names: Asp-B28; NovoLog; NovoRapid

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gestational diabetes; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 06 Nov 2023 Efficacy data from a phase III trial in Type 2 diabetes mellitus and Type 1 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
  • 19 Oct 2020 Novo Nordisk plans a phase III trial for Type 2 diabetes mellitus and Type 1 diabetes mellitus (Combination therapy) in China (SC) (NCT04588259)
  • 09 Oct 2020 Novo Nordisk initiates enrolment in a phase III trial for Type 2 diabetes mellitus and Type 1 diabetes mellitus (Combination therapy) in China (SC) (NCT04588259)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top